Merck, with new breast cancer data, aims to rebound from FDA rejection

Merck & Co.'s immunotherapy Keytruda kept tumors from returning in a Phase 3 study of patients with a tough-to-treat form of early-stage breast cancer, positioning the drugmaker to again seek approval after regulators rejected the treatment earlier this year.